Team-based intervention for HIV care in hospitals

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study explores the impact of a team-based intervention called ARTAS on improving linkage to care for newly diagnosed HIV patients in an inpatient setting. The intervention aims to reduce hospital readmission rates by providing comprehensive support and resources to patients who are not currently receiving antiretroviral therapy. Participants will receive either the team-based ARTAS intervention or standard care during their hospital stay. The study focuses on patients who are newly diagnosed or not virally suppressed and have not been under the care of an HIV specialist recently.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* 18 years of age or greater
* newly diagnosed HIV
* Known diagnosis of HIV not on ART within 30 days of admission
* Known HIV and not virally suppressed based on interview
* Known HIV and has not been under the care of an HIV specialist within the past 6 months

Exclusion Criteria:

* All three criteria must be present for exclusion:
* virally suppressed
* actively taking ART
* are under active care of an HIV specialist within the last 6 months
* Less than 18 years of age (stand alone exclusion)

Where it's running

• Loma Linda University Medical Center
  Loma Linda, California, United States Recruiting

Study contacts

• Study coordinator: Jennifer Veltman, MD
• Email: jveltman@llu.edu
• Phone: 909 558 4000

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Camino HIV Prevention and Care Study

  This study tests a combined legal and peer-support program to help Latin American adults in DC and the Bay Area improve HIV testing, PrEP use, and care engagement.

  Recruiting American University · Berkeley, California and 1 other locations · NCT07834853

• VH4367310 in healthy adults: testing single increasing doses for safety and how it behaves in the body

  This study tests a single rising dose of VH4367310, a cabotegravir prodrug, to see how it behaves in the body and how safe and tolerable it is in healthy adults aged 18 to 55.

  Recruiting at 2 sites Phase 1 ViiV Healthcare · Glendale, California and 1 other locations · NCT07818915

• Online cohort of sexual and gender minorities testing digital support to boost PrEP and ART use

  In Brazil, sexually and gender diverse adults are being followed online to see if weekly WhatsApp reminders help people stick to PrEP or ART.

  Recruiting Oswaldo Cruz Foundation · Rio de Janeiro, Rio de Janeiro · NCT07772791

• Metabolic Liver Disease in People Newly Diagnosed with HIV

  This study tests whether HIV-infected adults who are starting ART are more likely to develop MASLD and related liver issues than HIV-negative adults over five years.

  Recruiting at 11 sites Guven Health Group · Ankara, Ankara and 10 other locations · NCT07737340

• Screen2Prevent: HIV screening for teens and young adults in emergency departments

  The study tests three ways of offering HIV screening to people aged 14–24 in emergency departments to see if it helps link them to PrEP or HIV treatment using digital health tools.

  Recruiting at 5 sites Westat · Tampa, Florida and 4 other locations · NCT07728123

• Long-acting LEN/TAB/ZAB vs CAB/RPV in adults with HIV-1 who are virologically suppressed on daily ART

  This study tests whether switching to a weekly-plus long-acting injectable regimen of lenacapavir, teropavimab, and zinlirvimab works as well as a two-drug injectable regimen of cabotegravir and rilpivirine for adults with HIV-1 who already have undetectable virus on daily treatment.

  Recruiting at 19 sites Phase 3 Gilead Sciences · San Francisco, California and 18 other locations · NCT07682961

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.